Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia

Current Cancer Drug Targets

Volumn 13, Issue 1, 2013, Pages 69-79

  Kuroda, J ^a   Shimura, Y ^a   Yamamoto Sugitani, M ^a   Sasaki, N ^a   Taniwaki, M ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Apoptosis; Autophagy; CML; Gene instability; Microenvironment; Stem cell

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BAFETINIB; BCR ABL PROTEIN; BIM PROTEIN; CHEMOKINE RECEPTOR CXCR4; DASATINIB; GALECTIN 3; HEMOPOIETIC GROWTH FACTOR; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; ORGANIC CATION TRANSPORTER 1; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING;

APOPTOSIS; AUTOPHAGY; AUTOPHOSPHORYLATION; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DNA REPAIR; DRUG TARGETING; GENE MUTATION; HUMAN; MINIMAL RESIDUAL DISEASE; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

EID: 84875849302     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800913804486638     Document Type: Review

References (116)

1. Quintás-Cardama, A.; Cortes, J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009, 113 (8), 1619-1630.
2. Van Etten, R. A. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J. Exp. Med. 2007, 204 (3), 461-465.
3. Naldini, L.; Stacchini, A.; Cirillo, D. M.; Aglietta, M.; Gavosto, F.; Comoglio, P. M. Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells. Mol. Cell. Biol. 1986, 6 (5), 1803-1811.
4. Cortes, J. Natural history and staging of chronic myelogenous leukemia. Hematol. Oncol. Clin. North. Am. 2004, 18 (3), 569-584, viii.
5. Radich, J. P. The Biology of CML blast crisis. Hematology Am. Soc. Hematol. Educ. Program 2007, 384-391.
6. Tien, H. F.; Wang, C. H.; Chen, Y. C.; Shen, M. C.; Wu, H. S.; Lee, F. Y.; Chuang, S. M.; Liu, C. H. Chromosome and bcr rearrangement in chronic myelogenous leukaemia and their correlation with clinical states and prognosis of the disease. Br. J. Haematol. 1990, 75 (4), 469-475.
7. Makishima, H.; Jankowska, A. M.; McDevitt, M. A.; O'Keefe, C.; Dujardin, S.; Cazzolli, H.; Przychodzen, B.; Prince, C.; Nicoll, J.; Siddaiah, H.; Shaik, M.; Szpurka, H.; His, E.; Advani, A.; Paquette, R.; Maciejewski, J. P. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011, 117 (21), e198-206.
8. Sessarego, M.; Panarello, C.; Coviello, D. A.; Boccaccio, P.; Ajmar, F. Karyotype evolution in CML: high frequency of translocations other than the Ph. Cancer. Genet. Cytogenet. 1987, 25 (1), 73-80.
9. Kantarjian, H. M.; Baccarani, M.; Jabbour, E.; Saglio, G.; Cortes, J. E. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin. Cancer Res. 2011, 17 (7), 1674-1683.
10. Mahon, F. X.; Réa, D.; Guilhot, J.; Guilhot, F.; Huguet, F.; Nicolini, F.; Legros, L.; Charbonnier, A.; Guerci, A.; Varet, B.; Etienne, G.; Reiffers, J.; Rousselot, P.; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11 (11), 1029-1035.
11. Ross, D. M.; Branford, S.; Seymour, J. F.; Schwarer A. P.; Arthur, C.; Bartley, P. A.; Slader, C.; Field, C.; Dang, P.; Filshie, R. J.; Mills, A. K.; Grigg, A. P.; Melo, J. V.; Hughes, T. P. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010, 24 (10), 1719-1724.
12. Jabbour, E.; Cortes, J.; Santos, F. P.; Jones, D.; O'Brien, S.; Rondon, G.; Popat, U.; Giralt, S.; Kebriaei, P.; Jones, R. B.; Kantarjian, H.; Champlin, R.; de Lima, M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2011, 117 (13), 3641-3647.
13. Stamatović, D.; Balint, B.; Tukić, L.; Elez, M.; Tarabar, O.; Todorović, M.; Todorić-Zivanović, B.; Ostojić, G.; Tatomirović, Z.; Marjanović, S.; Malesević, M. Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy. Vojnosanit Pregl. 2012, 69 (1), 37-42.
14. Faber, L. M.; van Luxemburg-Heijs, S. A.; Veenhof, W. F.; Willemze, R.; Falkenburg, J. H. Generation of CD4+ cytotoxic Tlymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995, 86 (7), 2821-2828.
15. Greenhalgh, C. J.; Alexander, W. S. Suppressors of cytokine signalling and regulation of growth hormone action. Growth Horm. IGF. Res. 2004, 14 (3), 200-206.
16. Yoshimura, A. Negative regulation of cytokine signaling. Clin. Rev. Allergy Immunol. 2005, 28, 205-220.
17. Taylor, C. M.; Keating, A. E. Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain. Biochemistry 2005, 44 (49), 16246-16256.
18. Schultheis, B.; Carapeti-Marootian, M.; Hochhaus, A.; Weisser, A.; Goldman, J. M.; Melo, J. V. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 2002, 99 (5), 1766-1775.
19. Sakai, I.; Takeuchi, K.; Yamauchi, H.; Narumi, H.; Fujita, S. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 2002, 100 (8), 2926-2931.
20. Roman-Gomez, J.; Jimenez-Velasco, A.; Castillejo, J. A.; Cervantes, F.; Barrios, M.; Colomer, D.; Heiniger, A.; Torres, A. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica 2004, 89 (1), 42-48.
21. Kelly, P. N.; Strasser, A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 2011, 18 (9), 1414-1424.
22. Kuroda, J.; Puthalakath, H.; Cragg, M. S.; Kelly, P. N.; Bouillet, P.; Huang, D. C.; Kimura, S.; Ottmann, O. G.; Druker, B. J.; Villunger, A.; Roberts, A. W.; Strasser, A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (40), 14907-14912.
23. Kuroda, J.; Kimura, S.; Strasser, A.; Andreeff, M.; O'Reilly, L. A.; Ashihara, E.; Kamitsuji, Y.; Yokota, A.; Kawata, E.; Takeuchi, M.; Tanaka, R.; Tabe, Y.; Taniwaki, M.; Maekawa, T. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ. 2007, 14 (9), 1667-1677.
24. Petros, A. M.; Olejniczak, E. T.; Fesik, S. W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 2004, 1644 (2-3), 83-94.
25. Huang, D. C.; Adams, J. M.; Cory, S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J. 1998, 17 (4), 1029-1039.
26. Kuwana, T.; Bouchier-Hayes, L.; Chipuk, J. E.; Bonzon, C.; Sullivan, B. A.; Green, D. R.; Newmeyer, D. D. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell. 2005, 17 (4), 525-535.
27. Willis, S. N.; Fletcher, J. I.; Kaufmann, T.; van Delft, M. F.; Chen, L.; Czabotar, P. E.; Ierino, H.; Lee, E. F.; Fairlie, W. D.; Bouillet, P.; Strasser, A.; Kluck, R. M.; Adams, J. M.; Huang, D. C. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007, 315 (5813), 856-859.
28. Youle, R. J.; Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9 (1), 47-59.
29. Adams, J. M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26 (9), 1324-13237.
30. Kuroda, J.; Taniwaki, M. Involvement of BH3-only proteins in hematologic malignancies. Crit. Rev. Oncol. Hematol. 2009, 71 (2), 89-101.
31. Shah, N. P.; Kasap, C.; Weier, C.; Balbas, M.; Nicoll, J. M.; Bleickardt, E.; Nicaise, C.; Sawyers, C. L. Transient potent BCRABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008, 14 (6), 485-493.
32. Belloc, F.; Moreau-Gaudry, F.; Uhalde, M.; Cazalis, L.; Jeanneteau, M.; Lacombe, F.; Praloran, V.; Mahon, F. X. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biol. Ther. 2007, 6 (6), 912-919.
33. Airiau, K.; Mahon, F. X.; Josselin, M.; Jeanneteau, M.; Turcq, B.; Belloc, F. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Exp. Hematol. 2012, 40 (5), 367-378.
34. Matsui, H.; Asou, H.; Inaba, T. Cytokines direct the regulation of Bim mRNA stability by heat-shock cognate protein 70. Mol. Cell 2007, 25 (1), 99-112.
35. Keeshan, K.; Cotter, T. G.; McKenna, S. L. High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion. Leukemia 2002, 16 (9), 1725-1734.
36. Salomoni, P.; Condorelli, F.; Sweeney, S. M.; Calabretta, B. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood 2000, 96 (2), 676-684.
37. San José-Eneriz, E.; Agirre, X.; Jiménez-Velasco, A.; Cordeu, L.; Martín, V.; Arqueros, V.; Gárate, L.; Fresquet, V.; Cervantes, F.; Martínez-Climent, J. A.; Heiniger, A.; Torres, A.; Prósper, F.; Roman-Gomez, J. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur. J. Cancer 2009, 45 (10), 1877-1889.
38. Kuroda, J.; Kimura, S.; Andreeff, M.; Ashihara, E.; Kamitsuji, Y.; Yokota, A.; Kawata, E.; Takeuchi, M.; Tanaka, R.; Murotani, Y.; Matsumoto, Y.; Tanaka, H.; Strasser, A.; Taniwaki, M.; Maekawa, T. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br. J. Haematol. 2008, 140 (2), 181-190.
39. Rabinowitz, J. D.; White, E. Autophagy and metabolism. Science 2010, 330 (6009), 1344-1348.
40. Lum, J. J.; Bauer, D. E.; Kong, M.; Harris, M. H.; Li, C.; Lindsten, T.; Thompson, C. B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005, 120 (2), 237-248.
41. Kamitsuji, Y.; Kuroda, J.; Kimura, S.; Toyokuni, S.; Watanabe, K.; Ashihara, E.; Tanaka, H.; Yui, Y.; Watanabe, M.; Matsubara, H.; Mizushima, Y.; Hiraumi, Y.; Kawata, E.; Yoshikawa, T.; Maekawa, T.; Nakahata, T.; Adachi, S. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ. 2008, 15 (11), 1712-1722.
42. Yu, Y.; Yang, L.; Zhao, M.; Zhu, S.; Kang, R.; Vernon, P.; Tang, D.; Cao, L. Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia 2012, in print.
43. Crowley, L. C.; Elzinga, B. M.; O'Sullivan, G. C.; McKenna, S. L. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. Am. J. Hematol. 2011, 86 (1), 38-47.
44. Can, G.; Ekiz, H. A.; Baran, Y. Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells. Hematology 2011, 16 (2), 95-99.
45. Sheng, Z.; Ma, L.; Sun, J. E.; Zhu, L. J.; Green, M. R. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood 2011, 118 (10), 2840-2848.
46. Burke, B. A.; Carroll, M. BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia 2010, 24 (6), 1105-1112.
47. Skorski T. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leuk. Lymphoma 2008, 49 (4), 610-614.
48. Slupianek, A.; Poplawski, T.; Jozwiakowski, S. K.; Cramer, K.; Pytel, D.; Stoczynska, E.; Nowicki, M. O.; Blasiak, J.; Skorski, T. BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Res. 2011, 71 (3), 842-851.
49. Takeda, N.; Shibuya, M.; Maru, Y. The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (1), 203-207.
50. Daboussi, F.; Dumay, A.; Delacôte, F.; Lopez, B. S. DNA doublestrand break repair signalling: the case of RAD51 post-translational regulation. Cell Signal. 2002, 14 (12), 969-975.
51. Poplawski, T.; Blasiak, J. BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells. Mol. Biol. Rep. 2010, 37 (5), 2309-2315.
52. Canitrot, Y.; Lautier, D.; Laurent, G.; Fréchet, M.; Ahmed, A.; Turhan, A. G.; Salles, B.; Cazaux, C.; Hoffmann, J. S. Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene 1999, 18 (17), 2676-2680.
53. Graham, S. M.; Vass, J. K.; Holyoake, T. L.; Graham, G. J. Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 2007, 25 (12), 3111-3120.
54. Villuendas, R.; Steegmann, J. L.; Pollán, M.; Tracey, L.; Granda, A.; Fernández-Ruiz, E.; Casado, L. F.; Martínez, J.; Martínez, P.; Lombardía, L.; Villalón, L.; Odriozola, J.; Piris, M. A. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 2006, 20 (6), 1047-1054.
55. Frank, O.; Brors, B.; Fabarius, A.; Li, L.; Haak, M.; Merk, S.; Schwindel, U.; Zheng, C.; Müller, M. C.; Gretz, N.; Hehlmann, R.; Hochhaus, A.; Seifarth, W. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 2006, 20 (8), 1400-1407.
56. Nieborowska-Skorska, M.; Stoklosa, T.; Datta, M.; Czechowska, A.; Rink, L.; Slupianek, A.; Koptyra, M.; Seferynska, I.; Krszyna, K.; Blasiak, J.; Skorski, T. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle 2006, 5 (9), 994-1000.
57. Skorski, T. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state. Leuk. Lymphoma 2011, 52 (Suppl 1), 23-29.
58. Perrotti, D.; Jamieson, C.; Goldman, J.; Skorski, T. Chronic myeloid leukemia: mechanisms of blastic transformation. J. Clin. Invest. 2010, 120 (7), 2254-2264.
59. Saglio, G.; Kim, D. W.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R. E.; Hochhaus, A.; Hughes, T. P.; Gallagher, N.; Hoenekopp, A.; Dong, M.; Haque, A.; Larson, R. A.; Kantarjian, H. M.; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2010, 362 (24), 2251-2259.
60. Kantarjian, H.; Shah, N. P.; Hochhaus, A.; Cortes, J.; Shah, S.; Ayala, M.; Moiraghi, B.; Shen, Z.; Mayer, J.; Pasquini, R.; Nakamae, H.; Huguet, F.; Boqué, C.; Chuah, C.; Bleickardt, E.; Bradley-Garelik, M. B.; Zhu, C.; Szatrowski, T.; Shapiro, D.; Baccarani, M. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2010, 362 (24), 2260-2270.
61. Kim, T. D.; Türkmen, S.; Schwarz, M.; Koca, G.; Nogai, H.; Bommer, C.; Dörken, B.; Daniel, P.; le Coutre, P. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosomepositive chronic myeloid leukemia. Haematologica 2010, 95, 582-588.
62. Ahn, J. S.; Kim, Y. K.; Lee, S. R.; Yu, L.; Yang, D. H.; Cho, S. H.; Shim, H. J.; Bae, W. K.; Lee, J. J.; Chung, I. J.; Shin, M. G.; Kim, H. J. Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity. Cancer Res. Treat. 2010, 42, 37-41.
63. Milojkovic, D.; Nicholson, E.; Apperley, J. F.; Holyoake, T. L.; Shepherd, P.; Drummond, M. W.; Szydlo, R.; Bua, M.; Foroni, L.; Reid, A.; Khorashad, J. S.; de Lavallade, H.; Rezvani, K.; Paliompeis, C.; Goldman, J. M.; Marin, D. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010, 95, 224-231.
64. Nair, R. R.; Tolentino, J.; Hazlehurst, L. A. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem. Pharmacol. 2010, 80 (5), 602-612.
65. Ishikawa, F.; Yoshida, S.; Saito, Y.; Hijikata, A.; Kitamura, H.; Tanaka, S.; Nakamura, R.; Tanaka, T.; Tomiyama, H.; Saito, N.; Fukata, M.; Miyamoto, T.; Lyons, B.; Ohshima, K.; Uchida, N.; Taniguchi, S.; Ohara, O.; Akashi, K.; Harada, M.; Shultz, L. D. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 2007, 25 (11), 1315-1321.
66. Ninomiya, M.; Abe, A.; Katsumi, A.; Xu, J.; Ito, M.; Arai, F.; Suda, T.; Ito, M.; Kiyoi, H.; Kinoshita, T.; Naoe, T. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 2007, 21 (1), 136-142.
67. Lundell, B. I.; McCarthy, J. B.; Kovach, N. L.; Verfaillie, C. M. Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation. Leukemia 1997, 11 (6), 822-829.
68. Damiano, J. S.; Hazlehurst, L. A.; Dalton, W. S. Cell adhesionmediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 2001, 15 (8), 1232-1239.
69. Jin, L.; Tabe, Y.; Konoplev, S.; Xu, Y.; Leysath, C. E.; Lu, H.; Kimura, S.; Ohsaka, A.; Rios, M. B.; Calvert, L.; Kantarjian, H.; Andreeff, M.; Konopleva, M. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol. Cancer Ther. 2008, 7 (1), 48-58.
70. Tabe, Y.; Jin, L.; Tsutsumi-Ishii, Y.; Xu, Y.; McQueen, T.; Priebe, W.; Mills, G. B.; Ohsaka, A.; Nagaoka, I.; Andreeff, M.; Konopleva, M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrowderived stromal cells. Cancer Res. 2007, 67 (2), 684-694.
71. Bewry, N. N.; Nair, R. R.; Emmons, M. F.; Boulware, D.; Pinilla-Ibarz, J.; Hazlehurst, L. A. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol. Cancer Ther. 2008, 7 (10), 3169-3175.
72. Wang, Y.; Cai, D.; Brendel, C.; Barett, C.; Erben, P.; Manley, P. W.; Hochhaus, A.; Neubauer, A.; Burchert, A. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 2007, 109 (5), 2147-2155.
73. Hazlehurst, L. A.; Argilagos, R. F.; Dalton, W. S. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br. J. Haematol. 2007, 136 (2), 269-275.
74. Takeuchi, M.; Kimura, S.; Kuroda, J.; Ashihara, E.; Kawatani, M.; Osada, H.; Umezawa, K.; Yasui, E.; Imoto, M.; Tsuruo, T.; Yokota, A.; Tanaka, R.; Nagao, R.; Nakahata, T.; Fujiyama, Y.; Maekawa, T. Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death Differ. 2010, 17 (7), 1211-1220.
75. Giuntoli, S.; Rovida, E.; Barbetti, V.; Cipolleschi, M. G.; Olivotto, M.; Dello Sbarba, P. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations. Leukemia 2006, 20 (7), 1291-1293.
76. Desplat, V.; Faucher, J. L.; Mahon, F. X.; Dello Sbarba, P.; Praloran, V.; Ivanovic, Z. Hypoxia modifies proliferation and differentiation of CD34(+) CML cells. Stem Cells 2002, 20 (4), 347-354.
77. Tanturli, M.; Giuntoli, S.; Barbetti, V.; Rovida, E.; Dello Sbarba P. Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia. PLoS One 2011, 6 (2), e17008.
78. Puissant, A.; Robert, G.; Auberger, P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle 2010, 9 (17), 3470-3478.
79. Yamamoto-Sugitani, M.; Kuroda, J.; Ashihara, E.; Nagoshi, H.; Kobayashi, T.; Matsumoto, Y.; Sasaki, N.; Shimura, Y.; Kiyota, M.; Nakayama, R.; Akaji, K.; Taki, T.; Uoshima, N.; Kobayashi, Y.; Horiike, S.; Maekawa, T.; Taniwaki, M. Galectin-3 induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (42), 17468-17473.
80. Fukumori, T.; Kanayama, H. O.; Raz, A. The role of galectin-3 in cancer drug resistance. Drug Resist. Updat. 2007, 10 (3), 101-108.
81. Dumic, J.; Dabelic, S.; Flögel, M. Galectin-3: an open-ended story. Biochim. Biophys. Acta. 2006, 1760 (4), 616-635.
82. Schmidt, T.; Kharabi Masouleh, B.; Loges, S.; Cauwenberghs, S.; Fraisl, P.; Maes, C.; Jonckx, B.; De Keersmaecker, K.; Kleppe, M.; Tjwa, M.; Schenk, T.; Vinckier, S.; Fragoso, R.; De Mol, M.; Beel, K.; Dias, S.; Verfaillie, C.; Clark, R. E.; Brümmendorf, T. H.; Vandenberghe, P.; Rafii, S.; Holyoake, T.; Hochhaus, A.; Cools, J.; Karin, M.; Carmeliet, G.; Dewerchin, M.; Carmeliet, P. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 2011, 19 (6), 740-753.
83. Colmone, A.; Amorim, M.; Pontier, A. L.; Wang, S.; Jablonski, E.; Sipkins, D. A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008, 322 (5909), 1861-1865.
84. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M. A.; Dick, J. E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367 (6464), 645-648.
85. Jørgensen, H. G.; Holyoake, T. L. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem. Soc. Trans. 2007, 35 (Pt 5), 1347-1351.
86. Jamieson, C. H.; Ailles, L. E.; Dylla, S. J.; Muijtjens, M.; Jones, C.; Zehnder, J. L.; Gotlib, J.; Li, K.; Manz, M. G.; Keating, A.; Sawyers, C. L.; Weissman, I. L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 2004, 351 (7), 657-667.
87. Lemoli, R. M.; Salvestrini, V.; Bianchi, E.; Bertolini, F.; Fogli, M.; Amabile, M.; Tafuri, A.; Salati, S.; Zini, R.; Testoni, N.; Rabascio, C.; Rossi, L.; Martin-Padura, I.; Castagnetti, F.; Marighetti, P.; Martinelli, G.; Baccarani, M.; Ferrari, S.; Manfredini, R. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34-cell population with intrinsic resistance to imatinib. Blood 2009, 114 (25), 5191-5200.
88. Corbin, A. S.; Agarwal, A.; Loriaux, M.; Cortes, J.; Deininger, M. W.; Druker, B. J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 2011, 121 (1), 396-409.
89. Copland, M.; Hamilton, A.; Elrick, L. J.; Baird, J. W.; Allan, E. K.; Jordanides, N.; Barow, M.; Mountford, J. C.; Holyoake, T. L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107 (11), 4532-4539.
90. Michor, F.; Hughes, T. P.; Iwasa, Y.; Branford, S.; Shah, N. P.; Sawyers, C. L.; Nowak, M. A. Dynamics of chronic myeloid leukaemia. Nature 2005, 435 (7046), 1267-1270.
91. Roeder, I.; Horn, M.; Glauche, I.; Hochhaus, A.; Mueller, M. C.; Loeffler, M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 2006, 12 (10), 1181-1184.
92. Chomel, J. C.; Bonnet, M. L.; Sorel, N.; Bertrand, A.; Meunier, M. C.; Fichelson, S.; Melkus, M.; Bennaceur-Griscelli, A.; Guilhot, F.; Turhan, A. G. Leukemic stem cell persistency in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011 118 (13), 3657-3660.
93. Engler, J. R.; Frede, A.; Saunders, V. A.; Zannettino, A. C.; Hughes, T. P.; White, D. L. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010, 24 (4), 765-770.
94. Bunting, K. D. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002, 20 (1), 11-20.
95. Engler, J. R.; Frede, A.; Saunders, V.; Zannettino, A.; White, D. L.; Hughes, T. P. The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. Blood 2010, 116 (15), 2776-2778.
96. White, D. L.; Dang, P.; Engler, J.; Frede, A.; Zrim, S.; Osborn, M.; Saunders, V. A.; Manley, P. W.; Hughes, T. P. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J. Clin. Oncol. 2010, 28 (16), 2761-2767.
97. Zhao, C.; Blum, J.; Chen, A.; Kwon, H. Y.; Jung, S. H.; Cook, J. M.; Lagoo, A.; Reya, T. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12 (6), 528-541.
98. Dierks, C.; Beigi, R.; Guo, G. R.; Zirlik, K.; Stegert, M. R.; Manley, P.; Trussell, C.; Schmitt-Graeff, A.; Landwerlin, K.; Veelken, H.; Warmuth, M. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14 (3), 238-249.
99. Su, W.; Meng, F.; Huang, L.; Zheng, M.; Liu, W.; Sun, H. Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through-catenin signaling. Exp. Hematol. 2012, 40 (5), 418-427.
100. Chen, Y.; Hu, Y.; Zhang, H.; Peng, C.; Li, S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet. 2009, 41 (7), 783-792.
101. Ito, K.; Bernardi, R.; Morotti, A.; Matsuoka, S.; Saglio, G.; Ikeda, Y.; Rosenblatt, J.; Avigan, D. E.; Teruya-Feldstein, J.; Pandolfi, P. P. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453 (7198), 1072-1078.
102. Peng, C.; Chen, Y.; Yang, Z.; Zhang, H.; Osterby, L.; Rosmarin, A. G.; Li, S. PTEN is a tumor suppressor in CML stem cells and BCRABL-induced leukemias in mice. Blood 2010, 115 (3), 626-635.
103. Samanta, A. K.; Chakraborty, S. N.; Wang, Y.; Kantarjian, H.; Sun, X.; Hood, J.; Perrotti, D.; Arlinghaus, R. B. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 2009, 28 (14), 1669-1681.
104. Neviani, P.; Santhanam, R.; Trotta, R.; Notari, M.; Blaser, B. W.; Liu, S.; Mao, H.; Chang, J. S.; Galietta, A.; Uttam, A.; Roy, D. C.; Valtieri, M.; Bruner-Klisovic, R.; Caligiuri, M. A.; Bloomfield, C. D.; Marcucci, G.; Perrotti, D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8 (5), 355-368.
105. Neviani, P.; Santhanam, R.; Oaks, J. J.; Eiring, A. M.; Notari, M.; Blaser, B. W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti-Passerini, C.; Druker, B. J.; Cortes, J.; Marcucci, G.; Chen, C. S.; Verrills, N. M.; Roy, D. C.; Caligiuri, M. A.; Bloomfield, C. D.; Byrd, J. C.; Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest. 2007, 117 (9), 2408-2421.
106. Yong, A. S.; Keyvanfar, K.; Hensel, N.; Eniafe, R.; Savani, B. N.; Berg, M.; Lundqvist, A.; Adams, S.; Sloand, E. M.; Goldman, J. M.; Childs, R.; Barrett, A. J. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 2009, 113 (4), 875-882.
107. Esposito, N.; Colavita, I.; Quintarelli, C.; Sica, A.R.; Peluso, A. L.; Luciano, L.; Picardi, M.; Del Vecchio, L.; Buonomo, T.; Hughes, T. P.; White, D.; Radich, J. P.; Russo, D.; Branford, S.; Saglio, G.; Melo, J. V.; Martinelli, R.; Ruoppolo, M.; Kalebic, T.; Martinelli, G.; Pane, F. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood 2011, 118 (13), 3634-3644.
108. Warsch, W.; Kollmann, K.; Eckelhart, E.; Fajmann, S.; Cerny-Reiterer, S.; Hölbl, A.; Gleixner, K.V.; Dworzak, M.; Mayerhofer, M.; Hoermann, G.; Herrmann, H.; Sillaber, C.; Egger, G.; Valent, P.; Moriggl, R.; Sexl, V. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011, 117 (12), 3409-3420.
109. Quentmeier, H.; Eberth, S.; Romani, J.; Zaborski, M; Drexler, H. G. BCR-ABL1-independent PI3Kinase activation causing imatinibresistance. J. Hematol. Oncol. 2011, 4, 6-15.
110. Donato, N. J.; Wu, J. Y.; Stapley, J.; Gallick, G.; Lin, H.; Arlinghaus, R.; Talpaz, M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101 (2), 690-698.
111. Dai, Y.; Rahmani, M.; Corey, S. J.; Dent, P.; Grant, S. A Bcr/Ablindependent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.J. Biol. Chem. 2004, 279 (33), 34227-34239.
112. Mahon, F. X.; Hayette, S.; Lagarde, V.; Belloc, F.; Turcq, B.; Nicolini, F.; Belanger, C.; Manley, P. W.; Leroy, C.; Etienne, G.; Roche, S.; Pasquet, J. M. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 2008, 68 (23), 9809-9816.
113. Gioia, R.; Leroy, C.; Drullion, C.; Lagarde, V.; Etienne, G.; Dulucq, S.; Lippert, E.; Roche, S.; Mahon, F. X.; Pasquet, J. M. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 2011, 118 (8), 2211-2221.
114. Wu, J.; Meng, F.; Lu, H.; Kong, L.; Bornmann, W.; Peng, Z.; Talpaz, M.; Donato, N. J. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinibresistant chronic myelogenous leukemia cells. Blood 2008, 111 (7), 3821-3829
115. Deguchi, Y.; Kimura, S.; Ashihara, E.; Niwa, T.; Hodohara, K.; Fujiyama, Y.; Maekawa, T. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk. Res. 2008, 32 (6), 980-983.
116. Tabe, Y.; Jin, L.; Iwabuchi, K.; Wang, R. Y.; Ichikawa, N.; Miida, T.; Cortes, J.; Andreeff, M.; Konopleva, M. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia 2012, 26 (5), 883-892.